Alnylam continues scientific leadership in advancement of rnai therapeutics at the 17th annual meeting of the oligonucleotides therapeutics society

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today new pre-clinical research results demonstrating continued rnai therapeutics platform innovation and scientific leadership. the research was presented at the 17th annual meeting of the oligonucleotide therapeutics society (ots), held virtually from september 26 – 29, 2021. among the presentations from alnylam scientists, new pre-clinical data were presented iden
ALNY Ratings Summary
ALNY Quant Ranking